525: Rule Number One: Follow the Science | Kimi Iguchi, CFO, Sage Therapeutics
CFOTL: Help us to understand what sets Sage and its offerings apart?
Iguchi: In eight years we’ve developed a company that’s at about nine and a half billion dollars in market cap. We are really well positioned from a cash perspective, and we’ve grown to over 650 people strong. Let me tell you a little bit about the history here. We are focused on developing innovative medicines for brain disorders. When we started the company eight years ago, there was a total innovation void. Companies had had many, many failures, and they were shedding their CNS pipelines. Everyone was saying that brain…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.